Major trial to find best drug for rare autoimmune disease
Disease control
Not yet recruiting
This study compares five FDA-approved drugs (rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab) to see which one works best to prevent relapses in people with NMOSD, a rare autoimmune condition that can cause vision loss and paralysis. About 160 adults who test p…
Phase: PHASE4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 02, 2026 11:40 UTC